Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/6857625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551192286199808 |
|---|---|
| author | Joo Young Jung Min-Hee Ryu Baek-Yeol Ryoo Boram Han Ji Woong Cho Man Sup Lim Hyun Lim Ho Suk Kang Min-Jeong Kim Hong Il Ha Hunho Song Jung Han Kim Hyeong Su Kim Yoon-Koo Kang Dae Young Zang |
| author_facet | Joo Young Jung Min-Hee Ryu Baek-Yeol Ryoo Boram Han Ji Woong Cho Man Sup Lim Hyun Lim Ho Suk Kang Min-Jeong Kim Hong Il Ha Hunho Song Jung Han Kim Hyeong Su Kim Yoon-Koo Kang Dae Young Zang |
| author_sort | Joo Young Jung |
| collection | DOAJ |
| description | Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and Methods. We reviewed the data of patients who had previously been treated with first-line DS/DOS and received biweekly irinotecan-based chemotherapy (FOLFIRI/IFL) between October 2004 and November 2011. Results. A total of 209 cycles were administered to 35 patients, with a median of 4 (range, 1–22) cycles each. The overall response rate in 29 response-assessable patients was 17.2%, including 2 complete and 3 partial responses. The median progression-free and overall survivals were 3.81 (95% confidence interval [CI], 1.82–5.80) months and 6.24 (95% CI, 1.44–11.04) months, respectively. The major grade 3/4 toxicity was neutropenia (8.6%). Conclusion. FOLFIRI/IFL chemotherapy showed modest antitumour activity and tolerable toxicities in DS/DOS-treated MGC patients. |
| format | Article |
| id | doaj-art-711e0428a80c4a438f4140ed058c3568 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-711e0428a80c4a438f4140ed058c35682025-02-03T06:04:48ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/68576256857625Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1Joo Young Jung0Min-Hee Ryu1Baek-Yeol Ryoo2Boram Han3Ji Woong Cho4Man Sup Lim5Hyun Lim6Ho Suk Kang7Min-Jeong Kim8Hong Il Ha9Hunho Song10Jung Han Kim11Hyeong Su Kim12Yoon-Koo Kang13Dae Young Zang14Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Surgery, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Radiology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of KoreaBackground. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and Methods. We reviewed the data of patients who had previously been treated with first-line DS/DOS and received biweekly irinotecan-based chemotherapy (FOLFIRI/IFL) between October 2004 and November 2011. Results. A total of 209 cycles were administered to 35 patients, with a median of 4 (range, 1–22) cycles each. The overall response rate in 29 response-assessable patients was 17.2%, including 2 complete and 3 partial responses. The median progression-free and overall survivals were 3.81 (95% confidence interval [CI], 1.82–5.80) months and 6.24 (95% CI, 1.44–11.04) months, respectively. The major grade 3/4 toxicity was neutropenia (8.6%). Conclusion. FOLFIRI/IFL chemotherapy showed modest antitumour activity and tolerable toxicities in DS/DOS-treated MGC patients.http://dx.doi.org/10.1155/2016/6857625 |
| spellingShingle | Joo Young Jung Min-Hee Ryu Baek-Yeol Ryoo Boram Han Ji Woong Cho Man Sup Lim Hyun Lim Ho Suk Kang Min-Jeong Kim Hong Il Ha Hunho Song Jung Han Kim Hyeong Su Kim Yoon-Koo Kang Dae Young Zang Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 Gastroenterology Research and Practice |
| title | Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 |
| title_full | Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 |
| title_fullStr | Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 |
| title_full_unstemmed | Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 |
| title_short | Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 |
| title_sort | second line irinotecan leucovorin and 5 fluorouracil for gastric cancer patients after failed docetaxel and s 1 |
| url | http://dx.doi.org/10.1155/2016/6857625 |
| work_keys_str_mv | AT jooyoungjung secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT minheeryu secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT baekyeolryoo secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT boramhan secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT jiwoongcho secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT mansuplim secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT hyunlim secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT hosukkang secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT minjeongkim secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT hongilha secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT hunhosong secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT junghankim secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT hyeongsukim secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT yoonkookang secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 AT daeyoungzang secondlineirinotecanleucovorinand5fluorouracilforgastriccancerpatientsafterfaileddocetaxelands1 |